Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum LPLDL
- Development stage
- Unknown
- Lead developer
- OptiBiotix Health
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum LPLDL is a patented probiotic strain developed by ProBiotix Health, a subsidiary of OptiBiotix Health. Originally isolated from vegetable juice and selected using the proprietary OptiScreen technology platform, this strain is characterized by its high bile salt hydrolase (BSH) activity and its ability to survive the harsh conditions of the gastrointestinal tract. Its primary mechanism of action involves the deconjugation of bile salts in the gut; because deconjugated bile salts are poorly reabsorbed, the liver is forced to utilize systemic cholesterol to synthesize new bile acids, thereby reducing circulating levels of low-density lipoprotein (LDL) and total cholesterol. Clinical studies have demonstrated that LPLDL can significantly reduce multiple cardiovascular disease biomarkers, including LDL cholesterol, non-HDL cholesterol, and apolipoprotein B, in adults with hypercholesterolemia.
- Brand names
- YourBiotixYourBiotixCHYourBiotixBPYourBiotixVHYourBiotixMHYourBiotix InstaMeltYourBiotixX3YourBiotixX-3YourBiotixX 3
- Other names
- L. plantarum LPLDL
02
Targets
BSH (Bile salt hydrolase)
Beyond the preview
Go deeper on Lactobacillus plantarum LPLDL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum LPLDL.